Tirzepatide vs Tadalafil: side-by-side comparison
Tirzepatide (GIP/GLP-1 dual receptor agonist) and Tadalafil (PDE5 inhibitor) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Tirzepatide | Tadalafil |
|---|---|---|
| Therapeutic class | GIP/GLP-1 dual receptor agonist | PDE5 inhibitor |
| CAS | 2023788-19-2 | 171596-29-5 |
| ATC | A10BX16 | G04BE08 |
| Molecular weight | 4813.5 g/mol | 389.4 g/mol |
| Brands with this active ingredient | 1 | 7 |
What they share
Tirzepatide and Tadalafil share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Tirzepatide acts by a different mechanism than Tadalafil, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Tirzepatide: Tirzepatide binds with high affinity to the GIP receptor and to the GLP-1 receptor. Tadalafil: Tadalafil selectively inhibits PDE5, the enzyme responsible for breaking down cyclic guanosine monophosphate in the corpus cavernosum and other vascular smooth muscle.
Indications compared
Tirzepatide: Tirzepatide is approved in adults with type 2 diabetes mellitus, as monotherapy or in combination with other antidiabetic agents, to improve glycaemic control. Tadalafil: Tadalafil is approved for three indications: erectile dysfunction in adult men, lower urinary tract symptoms associated with benign prostatic hyperplasia, and pulmonary arterial hypertension.
Safety profile
Tirzepatide: The most common adverse effects are gastrointestinal: nausea, diarrhoea, vomiting, decreased appetite, constipation and abdominal discomfort, generally mild to moderate and most pronounced during dose escalation. Tadalafil: Common adverse effects in clinical trials include headache, dyspepsia, back pain, myalgia, nasal congestion and facial flushing.
Frequently asked questions
Is Tirzepatide better than Tadalafil? ▾
Tirzepatide and Tadalafil are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Tirzepatide and Tadalafil be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Tirzepatide
Products with Tadalafil
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.